Summary

Persistence Market Research presents an exhaustive analysis of the global Antibodies Contract Manufacturing Market, providing deep insights into market dynamics, key growth drivers, challenges, and emerging trends. This report serves as a valuable resource for stakeholders, offering detailed data and statistics to navigate the market landscape from 2024 to 2033.

Key Insights:

• Estimated Market Value (2024): USD 6.07 Billion
• Projected Market Value (2033): USD 17.5 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 12.5%

Antibodies Contract Manufacturing Market - Report Scope:

The rising demand for monoclonal antibodies (mAbs) for treating various chronic diseases, including cancer, autoimmune disorders, and infectious diseases, drives the market for antibodies contract manufacturing. Outsourcing manufacturing processes to contract manufacturing organizations (CMOs) enables pharmaceutical and biotechnology companies to focus on core competencies such as research and development, while CMOs provide specialized production capabilities, scalability, and compliance with regulatory standards. This approach not only enhances operational efficiency but also reduces time-to-market for new therapies.

Market Growth Drivers:

The antibodies contract manufacturing market is driven by several factors, including the increasing prevalence of chronic diseases and the growing biopharmaceutical sector. The rise in the number of biotech startups and the trend towards personalized medicine significantly contribute to the demand for outsourced manufacturing services. Additionally, technological advancements in bioprocessing and the increasing complexity of antibody production processes make CMOs a vital part of the biopharmaceutical manufacturing landscape.
The cost-effectiveness of outsourcing manufacturing, along with the ability to access state-of-the-art facilities and expertise, further propels the market. Regulatory agencies' stringent quality requirements also encourage companies to partner with CMOs that possess the necessary certifications and compliance standards.

Market Restraints:

Despite its positive growth outlook, the antibodies contract manufacturing market faces challenges such as high initial investment costs and the complexity of antibody production processes. Maintaining consistent quality and ensuring regulatory compliance across different regions can be challenging for CMOs. Additionally, capacity constraints and supply chain disruptions can affect production timelines and cost efficiency.
Intellectual property concerns and the need for stringent confidentiality agreements can also pose hurdles for companies considering outsourcing. Moreover, competition from in-house manufacturing capabilities within large pharmaceutical companies may limit market growth to some extent.

Market Opportunities:

The antibodies contract manufacturing market presents significant opportunities for expansion and innovation. The increasing demand for biosimilars and the growing trend of antibody-drug conjugates (ADCs) offer lucrative opportunities for CMOs specializing in these areas. Expansion into emerging markets, where biopharmaceutical production capabilities are still developing, can provide substantial growth potential.
Technological advancements in single-use systems and continuous manufacturing processes offer opportunities to enhance production efficiency and reduce costs. Furthermore, strategic partnerships and collaborations between CMOs and biopharmaceutical companies can lead to the development of innovative solutions and new product offerings, driving market growth.

Key Questions Addressed in the Report:

• What is the Expected Value CAGR of the Antibodies Contract Manufacturing Market from 2024 to 2033?
• What are the Key Factors Driving the Growth of the Antibodies Contract Manufacturing Market?
• Which Region Holds the Largest Market Share in the Antibodies Contract Manufacturing Market?
• Who are the Key Players in the Global Antibodies Contract Manufacturing Market?
• What Strategies are Adopted by Leading Companies to Sustain Growth in the Antibodies Contract Manufacturing Market?

Competitive Landscape and Business Strategies:

Leading companies in the antibodies contract manufacturing market include Lonza Group, Boehringer Ingelheim, and Samsung Biologics. These companies focus on expanding their manufacturing capacities, investing in advanced bioprocessing technologies, and forming strategic partnerships to maintain their competitive edge.
Lonza Group, for instance, has made significant investments in expanding its mammalian manufacturing capabilities. Boehringer Ingelheim emphasizes the importance of innovation and quality in its manufacturing processes, while Samsung Biologics focuses on providing end-to-end solutions for biopharmaceutical companies.

Key Companies Profiled:

• Lonza Group
• Boehringer Ingelheim
• Samsung Biologics
• WuXi AppTec
• Catalent, Inc.
• Fujifilm Diosynth Biotechnologies
• AGC Biologics
• AbbVie Contract Manufacturing
• Thermo Fisher Scientific Inc.
• KBI Biopharma, Inc.

Antibodies Contract Manufacturing Market Segmentation:

Product:
• Monoclonal Antibodies
• Antibody Fragments
• Polyclonal Antibodies
Expression System:
• Mammalian
• Microbial
o Bacteria
o Yeast
Company Size:
• Small
• Mid-sized
• Large
• Very large
Scale of Operation:
• Preclinical
• Clinical
• Commercial
Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption/Usage Analysis
4.2. List of Trading Companies
4.3. List of Local Manufacturers and their Distribution Strategy/Locations
4.4. Key Regulatory Scenario
4.5. Value Chain Analysis
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Biopharmaceutical Contract Manufacturing Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Number of Healthcare Facilities
5.2.2. Emergence of New Infectious Diseases
5.2.3. Rise in Disposable Income
5.2.4. Key Players’ Historic Growth
5.2.5. New Product Approval/Launches
5.2.6. Growing Popularity of Healthcare Check-Ups
5.2.7. Product Adoption
5.2.8. Rise in Prevalence of Chronic and Lifestyle Diseases
5.2.9. Key Strategic Developments
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Expression System
6.1.3. By Company Size
6.1.4. By Scale of Operation
6.1.5. By Country
6.2. 2024 Market Scenario
7. Global Antibody Contract Manufacturing Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Product, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
8.3.1. Monoclonal Antibodies
8.3.2. Antibody Fragments
8.3.3. Polyclonal Antibodies
8.4. Market Attractiveness Analysis By Product
9. Global Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Expression System, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Expression System, 2024-2033
9.3.1. Mammalian
9.3.2. Microbial
9.3.2.1. Bacteria
9.3.2.2. Yeast
9.4. Market Attractiveness Analysis By Expression System
10. Global Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033, By Company Size
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Company Size, 2024-2033
10.3.1. Small
10.3.2. Mid-sized
10.3.3. Large
10.3.4. Very large
10.4. Market Attractiveness Analysis By Company Size
11. Global Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033, By Scale of Operation
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Scale of Operation, 2024-2033
11.3.1. Preclinical
11.3.2. Clinical
11.3.3. Commercial
11.4. Market Attractiveness Analysis By Scale of Operation
12. Global Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Expression System
13.3.4. By Company Size
13.3.5. By Scale of Operation
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Expression System
13.4.4. By Company Size
13.4.5. By Scale of Operation
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Antibody Contract Manufacturing Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Expression System
13.8.1.2.3. By Company Size
13.8.1.2.4. By Scale of Operation
13.8.2. Canada Antibody Contract Manufacturing Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Expression System
13.8.2.2.3. By Company Size
13.8.2.2.4. By Scale of Operation
14. Latin America Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Expression System
14.3.4. By Company Size
14.3.5. By Scale of Operation
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Expression System
14.4.4. By Company Size
14.4.5. By Scale of Operation
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Antibody Contract Manufacturing Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Expression System
14.8.1.2.3. By Company Size
14.8.1.2.4. By Scale of Operation
14.8.2. Brazil Antibody Contract Manufacturing Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Expression System
14.8.2.2.3. By Company Size
14.8.2.2.4. By Scale of Operation
14.8.3. Argentina Antibody Contract Manufacturing Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Expression System
14.8.3.2.3. By Company Size
14.8.3.2.4. By Scale of Operation
15. Europe Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By Expression System
15.3.4. By Company Size
15.3.5. By Scale of Operation
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Expression System
15.4.4. By Company Size
15.4.5. By Scale of Operation
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
15.8.1. Germany Antibody Contract Manufacturing Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Expression System
15.8.1.2.3. By Company Size
15.8.1.2.4. By Scale of Operation
15.8.2. Italy Antibody Contract Manufacturing Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Expression System
15.8.2.2.3. By Company Size
15.8.2.2.4. By Scale of Operation
15.8.3. France Antibody Contract Manufacturing Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Expression System
15.8.3.2.3. By Company Size
15.8.3.2.4. By Scale of Operation
15.8.4. U.K. Antibody Contract Manufacturing Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product
15.8.4.2.2. By Expression System
15.8.4.2.3. By Company Size
15.8.4.2.4. By Scale of Operation
15.8.5. Spain Antibody Contract Manufacturing Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Product
15.8.5.2.2. By Expression System
15.8.5.2.3. By Company Size
15.8.5.2.4. By Scale of Operation
15.8.6. BENELUX Antibody Contract Manufacturing Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Product
15.8.6.2.2. By Expression System
15.8.6.2.3. By Company Size
15.8.6.2.4. By Scale of Operation
15.8.7. Russia Antibody Contract Manufacturing Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Product
15.8.7.2.2. By Expression System
15.8.7.2.3. By Company Size
15.8.7.2.4. By Scale of Operation
16. East Asia Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Product
16.3.3. By Expression System
16.3.4. By Company Size
16.3.5. By Scale of Operation
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Expression System
16.4.4. By Company Size
16.4.5. By Scale of Operation
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
16.8.1. China Antibody Contract Manufacturing Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Expression System
16.8.1.2.3. By Company Size
16.8.1.2.4. By Scale of Operation
16.8.2. Japan Antibody Contract Manufacturing Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Expression System
16.8.2.2.3. By Company Size
16.8.2.2.4. By Scale of Operation
16.8.3. South Korea Antibody Contract Manufacturing Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Expression System
16.8.3.2.3. By Company Size
16.8.3.2.4. By Scale of Operation
17. South Asia Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Product
17.3.3. By Expression System
17.3.4. By Company Size
17.3.5. By Scale of Operation
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Expression System
17.4.4. By Company Size
17.4.5. By Scale of Operation
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
17.8.1. India Antibody Contract Manufacturing Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Expression System
17.8.1.2.3. By Company Size
17.8.1.2.4. By Scale of Operation
17.8.2. Indonesia Antibody Contract Manufacturing Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Expression System
17.8.2.2.3. By Company Size
17.8.2.2.4. By Scale of Operation
17.8.3. Malaysia Antibody Contract Manufacturing Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Expression System
17.8.3.2.3. By Company Size
17.8.3.2.4. By Scale of Operation
17.8.4. Thailand Antibody Contract Manufacturing Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Expression System
17.8.4.2.3. By Company Size
17.8.4.2.4. By Scale of Operation
18. Oceania Antibody Contract Manufacturing Market 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Expression System
18.3.4. By Company Size
18.3.5. By Scale of Operation
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Expression System
18.4.4. By Company Size
18.4.5. By Scale of Operation
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Players - Intensity Mapping
18.8. Country Level Analysis & Forecast
18.8.1. Australia Antibody Contract Manufacturing Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Expression System
18.8.1.2.3. By Company Size
18.8.1.2.4. By Scale of Operation
18.8.2. New Zealand Antibody Contract Manufacturing Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Expression System
18.8.2.2.3. By Company Size
18.8.2.2.4. By Scale of Operation
19. Middle East and Africa (MEA) Antibody Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2033
19.1. Introduction
19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Market Taxonomy 2024-2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Expression System
19.3.4. By Company Size
19.3.5. By Scale of Operation
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Expression System
19.4.4. By Company Size
19.4.5. By Scale of Operation
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Key Players - Intensity Mapping
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Antibody Contract Manufacturing Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Expression System
19.8.1.2.3. By Company Size
19.8.1.2.4. By Scale of Operation
19.8.2. Turkey Antibody Contract Manufacturing Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Expression System
19.8.2.2.3. By Company Size
19.8.2.2.4. By Scale of Operation
19.8.3. South Africa Antibody Contract Manufacturing Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Expression System
19.8.3.2.3. By Company Size
19.8.3.2.4. By Scale of Operation
19.8.4. North Africa Antibody Contract Manufacturing Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Expression System
19.8.4.2.3. By Company Size
19.8.4.2.4. By Scale of Operation
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. AMRI
21.2.1.1. Overview
21.2.1.2. Product Portfolio
21.2.1.3. Sales Footprint
21.2.1.4. Key Financials
21.2.1.5. SWOT Analysis
21.2.1.6. Strategy Overview
21.2.1.6.1. Marketing Strategy
21.2.1.6.2. Product Strategy
21.2.1.6.3. Channel Strategy
21.2.2. AGC Biologics
21.2.2.1. Overview
21.2.2.2. Product Portfolio
21.2.2.3. Sales Footprint
21.2.2.4. Key Financials
21.2.2.5. SWOT Analysis
21.2.2.6. Strategy Overview
21.2.2.6.1. Marketing Strategy
21.2.2.6.2. Product Strategy
21.2.2.6.3. Channel Strategy
21.2.3. Aldevron
21.2.3.1. Overview
21.2.3.2. Product Portfolio
21.2.3.3. Sales Footprint
21.2.3.4. Key Financials
21.2.3.5. SWOT Analysis
21.2.3.6. Strategy Overview
21.2.3.6.1. Marketing Strategy
21.2.3.6.2. Product Strategy
21.2.3.6.3. Channel Strategy
21.2.4. Eurofins CDMO
21.2.4.1. Overview
21.2.4.2. Product Portfolio
21.2.4.3. Sales Footprint
21.2.4.4. Key Financials
21.2.4.5. SWOT Analysis
21.2.4.6. Strategy Overview
21.2.4.6.1. Marketing Strategy
21.2.4.6.2. Product Strategy
21.2.4.6.3. Channel Strategy
21.2.5. Boehringer Ingelheim BioXcellence
21.2.5.1. Overview
21.2.5.2. Product Portfolio
21.2.5.3. Sales Footprint
21.2.5.4. Key Financials
21.2.5.5. SWOT Analysis
21.2.5.6. Strategy Overview
21.2.5.6.1. Marketing Strategy
21.2.5.6.2. Product Strategy
21.2.5.6.3. Channel Strategy
21.2.6. FUJIFILM Diosynth Biotechnologies
21.2.6.1. Overview
21.2.6.2. Product Portfolio
21.2.6.3. Sales Footprint
21.2.6.4. Key Financials
21.2.6.5. SWOT Analysis
21.2.6.6. Strategy Overview
21.2.6.6.1. Marketing Strategy
21.2.6.6.2. Product Strategy
21.2.6.6.3. Channel Strategy
21.2.7. Emergent BioSolutions
21.2.7.1. Overview
21.2.7.2. Product Portfolio
21.2.7.3. Sales Footprint
21.2.7.4. Key Financials
21.2.7.5. SWOT Analysis
21.2.7.6. Strategy Overview
21.2.7.6.1. Marketing Strategy
21.2.7.6.2. Product Strategy
21.2.7.6.3. Channel Strategy
21.2.8. KBI Biopharma
21.2.8.1. Overview
21.2.8.2. Product Portfolio
21.2.8.3. Sales Footprint
21.2.8.4. Key Financials
21.2.8.5. SWOT Analysis
21.2.8.6. Strategy Overview
21.2.8.6.1. Marketing Strategy
21.2.8.6.2. Product Strategy
21.2.8.6.3. Channel Strategy
21.2.9. Lonza
21.2.9.1. Overview
21.2.9.2. Product Portfolio
21.2.9.3. Sales Footprint
21.2.9.4. Key Financials
21.2.9.5. SWOT Analysis
21.2.9.6. Strategy Overview
21.2.9.6.1. Marketing Strategy
21.2.9.6.2. Product Strategy
21.2.9.6.3. Channel Strategy
21.2.10. Novasep
21.2.10.1. Overview
21.2.10.2. Product Portfolio
21.2.10.3. Sales Footprint
21.2.10.4. Key Financials
21.2.10.5. SWOT Analysis
21.2.10.6. Strategy Overview
21.2.10.6.1. Marketing Strategy
21.2.10.6.2. Product Strategy
21.2.10.6.3. Channel Strategy
21.2.11. Nitto Avecia Pharma Services
21.2.11.1. Overview
21.2.11.2. Product Portfolio
21.2.11.3. Sales Footprint
21.2.11.4. Key Financials
21.2.11.5. SWOT Analysis
21.2.11.6. Strategy Overview
21.2.11.6.1. Marketing Strategy
21.2.11.6.2. Product Strategy
21.2.11.6.3. Channel Strategy
21.2.12. Pierre Fabre
21.2.12.1. Overview
21.2.12.2. Product Portfolio
21.2.12.3. Sales Footprint
21.2.12.4. Key Financials
21.2.12.5. SWOT Analysis
21.2.12.6. Strategy Overview
21.2.12.6.1. Marketing Strategy
21.2.12.6.2. Product Strategy
21.2.12.6.3. Channel Strategy
21.2.13. Samsung BioLogics
21.2.13.1. Overview
21.2.13.2. Product Portfolio
21.2.13.3. Sales Footprint
21.2.13.4. Key Financials
21.2.13.5. SWOT Analysis
21.2.13.6. Strategy Overview
21.2.13.6.1. Marketing Strategy
21.2.13.6.2. Product Strategy
21.2.13.6.3. Channel Strategy
21.2.14. Synthon
21.2.14.1. Overview
21.2.14.2. Product Portfolio
21.2.14.3. Sales Footprint
21.2.14.4. Key Financials
21.2.14.5. SWOT Analysis
21.2.14.6. Strategy Overview
21.2.14.6.1. Marketing Strategy
21.2.14.6.2. Product Strategy
21.2.14.6.3. Channel Strategy
21.2.15. Thermo Fisher Scientific
21.2.15.1. Overview
21.2.15.2. Product Portfolio
21.2.15.3. Sales Footprint
21.2.15.4. Key Financials
21.2.15.5. SWOT Analysis
21.2.15.6. Strategy Overview
21.2.15.6.1. Marketing Strategy
21.2.15.6.2. Product Strategy
21.2.15.6.3. Channel Strategy
21.2.16. AbbVie, Inc.
21.2.16.1. Overview
21.2.16.2. Product Portfolio
21.2.16.3. Sales Footprint
21.2.16.4. Key Financials
21.2.16.5. SWOT Analysis
21.2.16.6. Strategy Overview
21.2.16.6.1. Marketing Strategy
21.2.16.6.2. Product Strategy
21.2.16.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology